Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASES: FOCUS ON ATRIAL FIBRILLATION

https://doi.org/10.20996/1819-6446-2015-11-2-196-201

Full Text:

Abstract

The question of mutual influence of risk factors for cardiovascular and renal diseases with a focus on atrial fibrillation is considered. Modern approaches to the prevention of major macrovascular events in patients with comorbidity are evaluated.

About the Author

V. N. Shishkova
Center for Speech Pathology and Neurorehabilitation
Russian Federation
Nikoloyamskaya ul. 20, Moscow, 113262 Russia


References

1. Moiseyev VS, Kobalava ZD. Cardiorenal syndrome (renal factor and increased risk of cardiovascular disease). Klinicheskaya Farmakologiya i Terapiya 2002; 11 (3): 16-8. Russian (Моисеев В.С., Кобала-ва Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клиническая Фармакология и Терапия 2002; 11(3): 16-8).

2. Mukhin NA, Moiseyev VS, Kobalava ZD. Cardiorenal interactions: clinical significance and role in the pathogenesis of diseases of the cardiovascular system and kidneys. Terapevticheskiy Arkhiv 2004; 6: 39-46. Russian (Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Терапевтический Архив 2004; 6: 39-46).

3. Mukhin NA. Decreased glomerular filtration rate - population-wide marker of poor prognosis. Terapevticheskiy Arkhiv 2007; 6: 5-10. Russian (Мухин Н.А. Снижение скорости клубочковой фильтрации – общепопуляционный маркер неблагоприятного прогноза Терапевтический Ар-хив 2007; 6: 5-10).

4. Ronco C, McCullough P, Anker S. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31:703-11.

5. Sarnak MJ, Levey AS, Schoolwerth AC. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-65.

6. Segura J, Garcia-Donair J, Praga M. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol 2006;17 (Suppl 2.):136-40.

7. Go AS, Chertow GM, Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.

8. Cardiovascular risk and chronic kidney disease: strategies cardiac and renal protection. Rossiyskiy Kardiologicheskiy Zhurnal 2014; 8 (112): 7-37. Russian (Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский Кардиологический Журнал 2014; 8 (112): 7-37).

9. WHO-FIC Network at the annual meeting in Trieste, October 2007. Available at: http://www.who.int/classifications/icd/ICD-10%20Updates%202007.pdf. Accessed by 09.04.2015

10. Matsushita K, van der Velde M, Astor BC. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731):2073-81.

11. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. KidneyInt 2013;3:1-305.

12. Chronic kidney disease: the basic principles of screening, diagnosis, prevention and treatment approaches. Russian recommendations. Nefrologiya 2012; 16 (1): 89-115. Russian (Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Рос-сийские рекомендации. Нефрология 2012; 16(1): 89-115).

13. Watanabe H., Watanabe T., Sasaki S. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009; 158(4): 629–36.

14. Iguchi Y., Kimura K., Kobayashi K. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102(8):1056–9.

15. Tsagalis G, Bakirtzi N, Manios E, et al. Atrial fibrillation in chronic hemodialysis patients: prevalence, types, predictors, and treatment practices in Greece. Artif Organs 2011; 35: 916-22.

16. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946-53.

17. Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27: 3816-22.

18. Go AS, Fang MC, Udaltsova N, et al.; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-9.

19. Olesen JB, Lip GY, Kamper AL. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367(7):625-35.

20. Tsagalis G, Akrivos T, Alevizaki M, et al. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. Nephrol Dial Transplant 2009; 24: 194-200.

21. Kumai Y, Kamouchi M, Hata J, et al.; FSR Investigators. Proteinuria and clinical outcomes after ischemic stroke. Neurology 2012; 78: 1909-15.

22. Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 2009; 40: 1296-303.

23. Bukowska A., Lendeckel U., Krohn A.Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney. Europace 2008; 10(10): 1212–7.

24. Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007; 38: 3127-32.

25. Shimizu Y, Maeda K, Imano H, et al. Chronic kidneydisease and drinking status in relation to risks of stroke and its subtypes: the Circulatory Risk in Communities Study (CIRCS). Stroke 2011; 42: 2531-7.

26. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb Haemost 2013;110(5):1074-9.

27. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. EurHeartJ 2012; 33: 1500-10.

28. Diagnosis and treatment of atrial fibrillation. Russian recommendations. Rossiyskiy Kardiologicheskiy Zhurnal 2013; 4 (102): suppl 3: 1-45. Russian (Диагностика и лечение фибрилляций предсер-дий. Российские рекомендации. Российский Кардиологический Журнал 2013; 4(102): при-ложение 3: 1-45).

29. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625–51.

30. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81.

31. Mueck W., Lensing A.W., Agnelli G., et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50:675-86.

32. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-30.

33. Boytsov S.A., Yakushin S.S., Martsevich S.Yu., et al. Outpatient register of cardiovascular diseases in the Ryazan region (RECVASA): principal tasks, experience of development and first results. Rational Pharmacother Card 2013;9(1):4-14. Russian (Бойцов С.А., Якушин C.С., Марцевич С.Ю. Амбу-латорно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты. Рациональная Фармакоте-рапия в Кардиологии 2013;9(1): 4-14).


For citation:


Shishkova V.N. CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASES: FOCUS ON ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2015;11(2):196-201. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-2-196-201

Views: 416


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)